Wegovy may have highest 'eye stroke' and sight loss risk among semaglutide GLP-1 agonists

Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of “eye stroke” (ischemic optic neuropathy) and sudden sight loss of the semaglutide drugs, finds an analysis of unintended side effect reports published in the British Journal…

Continue Reading

News Source: medicalxpress.com